A Phase II Study of BAY 43-9006 (NSC 724772) in Unresectable Stage III and IV Melanoma (IND 69,869).
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2013
At a glance
- Drugs Sorafenib (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 16 Jun 2011 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.
- 23 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.